Key factors
sym | ACOR |
exch | US |
MCap | 821.02K |
Beta | 1.462 |
EPS | -203.5 |
Div date | 0000-00-00 |
Yesterday
sym | ACOR |
exch | US |
50 Day MA | 10.22 |
200 Day MA | 12.78 |
52 Week High | 24.19 |
52 Week Low | 0.611 |
Target Price | 10.0 |
Market Cap Mln | 0.821 |
Share statistics
Shares Outstanding | 1242.1K |
Shares Float | 1215.47K |
Percent Institutions | 13.22 |
PercentInsiders | 0.689 |
SharesShort | 8102.0 |
Short Ratio | 1.84 |
Shares Short Prior Month | 9465.0 |
Short Percent | 0.659 |
Income
Revenue TTM | 117.63M |
Revenue Per Share TTM | 94.71 |
Quarterly Revenue Growth YOY | 20.70 |
Gross Profit TTM | 82.43M |
EBITDA | 8402.0K |
Diluted Eps TTM | -203.5 |
Quarterly Earnings Growth YOY | 587.30 |
earning
Operating Margin TTM | 0.039 |
PEGRatio | 0.51 |
Earnings Share | -203.5 |
Dividend
Dividend Date | 2021-01-04 |
Last Split Date | 2023-06-05 |
Last Split Factor | 1:20 |
business
Enterprise Value Ebitda | -0.69 |
Enterprise Value Revenue | 1.372 |
Book Value /share | -127.1 |
Price Book MRQ | 0.052 |
Price Sales TTM | 0.007 |
ProfitMargin | -2.14 |
ReturnOnAssetsTTM | -0.05 |
ReturnOnEquityTTM | -0.23 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Codes
ISIN | US00484M6012 |
CIK | 1008848 |
Code | ACOR |
CUSIP | 00484M106 |
Employer Id Number | 13-3831168 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 102.0 |
IPODate | 2006-02-10 |
International Domestic | Domestic |
MostRecent Quarter | 2024-03-31 |
Contact
Name | Acorda Therapeutics Inc |
Address | 2 Blue Hill Plaza, Pearl River, NY, United States, 10965 |
Country Name | USA |
Phone | 914 347 4300 |
Web URL | https://www.acorda.com |
Logo URL | /img/logos/US/ACOR.png |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.